ikonicacademy.kartra.com/page/0qt135

We’re pleased to announce the #NEWS that our investigational drug has met its primary endpoint in the Phase III FIGARO-DKD study in patients with chronic kidney disease and type 2 diabetes. Read more: bit.ly/3y13Wpu

With the positive outcome of the composite primary endpoint of the FIGARO-DKD trial, we have reached a significant milestone for finerenone by completing the largest Phase III clinical trial program to date focusing on chronic kidney disease and type 2... businesswire.com/news/home/2021…

Diabetic kidney disease is the leading cause of kidney failure. This article highlights treatment, opportunities for patients, possible advancements in kidney health, and introduces the launch of the Diabetic Kidney Disease Collaborative at American Society of Nephrology bit.ly/CJN18641120

👏👏 to @yhandelsmanmd for assembling such a distinguished group of experts to discuss practical ways to reduce CV risk across #diabetes, #ckd, #lipids, #bloodpressure! TMIOA 🧬 World Congress on IR, DM & CVD 🌎 @heartindiabetes Healio

👥 with HFrEF EF & kidney disease 👉not optimally treated with evidence-based medical therapies 👉even at levels of eGFR where such therapies would not be contraindicated by kidney dysfunction 💪efforts are required to mitigate risk in comorbid HF & kidney disease Soc Esp Cardiología

#ESCCongress #HotLine #FIGARO-DKD Dr. Pitt U-M Health Frankel CVC 🫀 Finerenone (MRA) in CKD & DM=nonsteroidal MRA 🫀7437 pt, exclude HF, >👨🆚💃, eGFR >25 🫀62% had albuminuria with Normal eGFR 🫀 13%⬇️ 1o endpoint, driven by ⬇️🏥 🫀 progression to ESRD ⬇️ 🫀2X HyperK with Finerenone

#ESCCongress #HotLine #FIGARO-DKD High risk population: DM + CKD; residual risk #cvprev 🫀 well tolerated Finerenone, minimal side effect 🫀 Highlight need for early CKD tx with MRA 🫀 Must determine albuminuria with DM patients, even when eGFR normal NEJM MIЯVΛƬ #IC ༄ ｡°

FIGARO-DKD: Among patients w/ type 2 DM & stage 2-4 CKD w/ moderate albuminuria or stage 1-2 CKD w/ severe albuminuria, finerenone improved CV outcomes vs placebo ca. 2021 from NEJM #ESCCongress #ESCCongress2021 #Nephpearls #Cardiorenal 👉🏼 nejm.org/doi/full/10.10…

#ESCCongress FIDELITY pooled data presented by Rajiv Agarwal MD, MS & Gerasimos Filippatos ❇️Diabetic CKD+ albuminuria (40% with eGFR>60) 1-4 ❇️Finerenone ⬇️composite ❤️outcome by 14% (CV ☠️ 🏥) ❇️⬇️CKD progression by 23% Janani Rangaswami Swapnil Hiremath @hswapnil.medsky.social Dr. Christopher Wong Daniel Cuthbertson Harriette Van Spall, MD MPH 🇨🇦 Dr Rani Khatib FESC

UACR is cheaper than an echocardiogram. UACR identifies patients with T2D at risk for CVD. And now you can do something about it. It is no longer about just staging CKD. It is about saving hearts and kidneys. For a T2D, UACR is an important number to know

#FIGARODKD is a powerful testament to the value of #UACR testing in routine clinical care of #T2D David Berg Stephen Wiviott taught us in TIMI Study Group risk score that nothing beats #UACR in forecasting HF risk...not even knowledge of prior history of HF! ahajournals.org/doi/10.1161/CI…

Advocating for Health Equity in Kidney Care: An Urgent Need - Kidney Medicine kidneymedicinejournal.org/article/S2590-…

Congratulations to Debbie Allen, National Kidney Foundation partner and kidney health advocate, on her Governors Award at the Emmy Awards. #Emmys2021 #MinuteforYourKidneys

What role do endothelin-1 and angiotensin-II play in IgAN and can they be harnessed for therapy? Find out from the experts in this new activity! #PeerVoice #meded #nephrology #IgAN #IgAnephropathy peervoice.com/APY?&PromoCode…

Learning about IgA nephropathy from Dr. Lafayette GlomCon fellowship program.. 🙌⭐️⭐️ This is the beauty of GlomCon fellowship program we learn from the bests ⭐️in the field #nephtwitter #medtwitter

There are 150,000 biopsy-confirmed IgAN patients in the U.S. with several million more globally. @ChinookTx is dedicated to changing the course of kidney care for these patients by providing innovative treatment options. Learn more here: chinooktx.com #ISNWCN